Head-to-head evidence
amycretin vs CT-996
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
amycretin
Developed by Novo Nordisk
NCT06064006 · Phase 2 · completed
The study was randomized, quadruple-masked, and placebo-controlled, with 125 participants, providing a meaningful controlled design. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
This trial's registered primary endpoint was safety (treatment-emergent adverse events); the figures shown are its prespecified secondary weight-change endpoints as published in The Lancet.
Next expected readout: December 2027 · NCT07587710 (registry estimate)
CT-996
Developed by Roche
NCT07081958 · Phase 2 · completed
The study randomized 352 participants to placebo or one of seven RO7795081 dosing regimens, with participants and investigators blinded. Its primary endpoint was the clinical measure of percent change in body weight at Week 30, but no results or statistical comparison have been posted, so the endpoint cannot yet be classified as met or missed.
Next expected readout: December 2026 · NCT06982131 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: amycretin's landscape · CT-996's landscape